Evidence map›Paper›PMID 34937563›Full record

ArticleCancer cell international2021

miR-378d suppresses malignant phenotype of ESCC cells through AKT signaling.

Jie Peng, Susu Shi, Juan Yu, Jianli Liu, Haixiang Wei, Haixia Song, Shaoqiang Wang, Zhejie Li, Shujin He, Lei Li and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Jie Peng *Department of Pathology, Affiliated Hospital of Jining Medical University, Jining Medical University, 89 Guhuai Road, Jining, 272029, Shandong, China.
Susu Shi *Department of Pathology, Affiliated Hospital of Jining Medical University, Jining Medical University, 89 Guhuai Road, Jining, 272029, Shandong, China.
Juan Yu *Department of Pathology, Affiliated Hospital of Jining Medical University, Jining Medical University, 89 Guhuai Road, Jining, 272029, Shandong, China.
Jianli LiuDepartment of Pathology, Affiliated Hospital of Jining Medical University, Jining Medical University, 89 Guhuai Road, Jining, 272029, Shandong, China.
Haixiang WeiDepartment of Thoracic Surgery, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, 272029, Shandong, China.
Haixia SongDepartment of Thoracic Surgery, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, 272029, Shandong, China.
Shaoqiang WangDepartment of Thoracic Surgery, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, 272029, Shandong, China.
Zhejie LiDepartment of Pathology, Affiliated Hospital of Jining Medical University, Jining Medical University, 89 Guhuai Road, Jining, 272029, Shandong, China.
Shujin HeDepartment of Pathology, Affiliated Hospital of Jining Medical University, Jining Medical University, 89 Guhuai Road, Jining, 272029, Shandong, China.
Lei LiDepartment of Pathology, Affiliated Hospital of Jining Medical University, Jining Medical University, 89 Guhuai Road, Jining, 272029, Shandong, China.
Hongyan ZhangDepartment of Pathology, Affiliated Hospital of Jining Medical University, Jining Medical University, 89 Guhuai Road, Jining, 272029, Shandong, China.
Zhizhen YanDepartment of Pathology, Affiliated Hospital of Jining Medical University, Jining Medical University, 89 Guhuai Road, Jining, 272029, Shandong, China.
Ran ZhaoDepartment of Pathology, Affiliated Hospital of Jining Medical University, Jining Medical University, 89 Guhuai Road, Jining, 272029, Shandong, China.
Yukun LiuDepartment of Pathology, Affiliated Hospital of Jining Medical University, Jining Medical University, 89 Guhuai Road, Jining, 272029, Shandong, China.
Yanrong LiuDepartment of Pathology, Affiliated Hospital of Jining Medical University, Jining Medical University, 89 Guhuai Road, Jining, 272029, Shandong, China.
Junjun LiCancer Research Institute and School of Basic Medical Sciences, Central South University, Changsha, 410078, Hunan, China.
Renya ZhangDepartment of Pathology, Affiliated Hospital of Jining Medical University, Jining Medical University, 89 Guhuai Road, Jining, 272029, Shandong, China.
Wei WangDepartment of Pathology, Affiliated Hospital of Jining Medical University, Jining Medical University, 89 Guhuai Road, Jining, 272029, Shandong, China. wangwei@mail.jnmc.edu.cn.ORCID http://orcid.org/0000-0003-4728-4920

Funding

National Natural Science Foundation of China 81802945
6 · The paper itself

Abstract

backgroundPost-resistance progress in paclitaxel (PTX) treatment remains a major challenge in tumor treatment. A high dose of PTX was used for cell lines to analyze the changes in molecular expression. The miR-378d was sharply reduced in surviving cells, but the role of miR-378d in Esophageal squamous cell carcinoma (ESCC) remained unclear.

methodsWe analyzed the relationship between miR-378d expression and the clinicopathological features of ESCC. We constructed miR-378d silent expression cell lines to study phenotypes and molecular mechanisms.

resultsThe miR-378d expression was associated with good prognosis in patients with ESCC. miR-378d inhibition promoted chemo-resistance, monoclonal formation, EMT, migration, invasion, stemness, and metastasis of ESCC cells. miR-378d can target downregulated AKT1.

conclusionsTherefore, miR-378d expression is a good prognostic factor of patients with ESCC and regulates the malignant phenotype of tumor cells through AKT.

Indexed as

AKT1Chemo-resistanceESCCmiR-378dPrognosis

Identifiers

PMID34937563
PMCPMC8697470

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.